Literature DB >> 23574320

Specific antibody deficiency in children with recurrent respiratory infections: a controlled study with follow-up.

O Ruuskanen1, A Nurkka, M Helminen, M K Viljanen, H Käyhty, L Kainulainen.   

Abstract

Specific antibody deficiency (SAD) to unconjugated pneumococcal vaccine (PPV) is an established primary B cell immunodeficiency. The occurrence and natural history of SAD in children is unclear. We conducted an observational study to identify SAD in children with recurrent respiratory infections. Ninety-nine children, mean age 5·9 (range 2-16) years, with recurrent or severe infections were vaccinated with PPV; serum antibody concentrations for serotypes 4, 6B, 9V, 14, 18C, 19F and 23F were measured before and 2 weeks after vaccination with enzyme immunoassay. The retrospective control group consisted of 89 healthy children matched for age and gender. No children had received previous conjugated pneumococcal vaccine (PCV) or PPV. The structured history of infectious diseases of all participants was collected. Ten of 91 (11%) children (eight excluded due to immunoglobulin G subclass deficiency) with recurrent respiratory infections had SAD. In the control group, three children (3%) responded inadequately to PPV (P = 0·05). Most children with SAD also had many other minor immune defects. After 0·5-5 years (medium 3·8), eight children with SAD were revaccinated with PPV; five responded adequately and three inadequately. Two SAD children were revaccinated with PCV, one developed an adequate and one an inadequate response. Two children with SAD received treatment with intravenous immunoglobulin; the remaining eight children recovered without replacement therapy during the follow-up. SAD is common in young children with recurrent respiratory infections, but it is often transient and resolves itself within a few years without specific treatment.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574320      PMCID: PMC3628326          DOI: 10.1111/cei.12053

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Coexistence of (partial) immune defects and risk of recurrent respiratory infections.

Authors:  Xavier Bossuyt; Leen Moens; Erna Van Hoeyveld; Axel Jeurissen; Guy Bogaert; Kate Sauer; Marijke Proesmans; Marc Raes; Kris De Boeck
Journal:  Clin Chem       Date:  2006-11-16       Impact factor: 8.327

2.  Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens.

Authors:  Axel Jeurissen; Leen Moens; Marc Raes; Greet Wuyts; Luc Willebrords; Kate Sauer; Marijke Proesmans; Jan L Ceuppens; Kris De Boeck; Xavier Bossuyt
Journal:  Clin Chem       Date:  2007-01-26       Impact factor: 8.327

3.  Age- and serotype-dependent antibody response to pneumococcal polysaccharides.

Authors:  Xavier Bossuyt; Heleen Borgers; Leen Moens; Bert Verbinnen; Isabelle Meyts
Journal:  J Allergy Clin Immunol       Date:  2011-04       Impact factor: 10.793

4.  Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults.

Authors:  T Wuorimaa; H Käyhty; O Leroy; J Eskola
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

5.  The clinical syndrome of specific antibody deficiency in children.

Authors:  R J Boyle; C Le; A Balloch; M L-K Tang
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

6.  Increases in serum immunoglobulins to age-related normal levels in children with IgA and/or IgG subclass deficiency.

Authors:  Necil Kutukculer; Neslihan Edeer Karaca; Ozlem Demircioglu; Guzide Aksu
Journal:  Pediatr Allergy Immunol       Date:  2007-03       Impact factor: 6.377

7.  Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine.

Authors:  R U Sorensen; L E Leiva; P A Giangrosso; B Butler; F C Javier; D M Sacerdote; N Bradford; C Moore
Journal:  Pediatr Infect Dis J       Date:  1998-08       Impact factor: 2.129

8.  Intrathecal synthesis of antibodies to diphtheria and tetanus toxoids in multiple sclerosis patients.

Authors:  A Salmi; M Viljanen; M Reunanen
Journal:  J Neuroimmunol       Date:  1981-09       Impact factor: 3.478

9.  First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants.

Authors:  M Koskela; M Leinonen; V M Häivä; M Timonen; P H Mäkelä
Journal:  Pediatr Infect Dis       Date:  1986 Jan-Feb

10.  Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections.

Authors:  L A Sanders; G T Rijkers; W Kuis; A J Tenbergen-Meekes; B R de Graeff-Meeder; I Hiemstra; B J Zegers
Journal:  J Allergy Clin Immunol       Date:  1993-01       Impact factor: 10.793

View more
  13 in total

1.  Cartilage-hair hypoplasia: follow-up of immunodeficiency in two patients.

Authors:  Leena Kainulainen; Olli Lassila; Olli Ruuskanen
Journal:  J Clin Immunol       Date:  2014-01-09       Impact factor: 8.317

Review 2.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Authors:  Stephanie Albin; Charlotte Cunningham-Rundles
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

3.  Value of allohaemagglutinins in the diagnosis of a polysaccharide antibody deficiency.

Authors:  H Schaballie; F Vermeulen; B Verbinnen; G Frans; E Vermeulen; M Proesmans; K De Vreese; M P Emonds; K De Boeck; L Moens; C Picard; X Bossuyt; I Meyts
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

4.  The Challenge of Immunoglobulin-G Subclass Deficiency and Specific Polysaccharide Antibody Deficiency--a Dutch Pediatric Cohort Study.

Authors:  Ellen J H Schatorjé; Everieke de Jong; Roeland W N M van Hout; Yumely García Vivas; Esther de Vries
Journal:  J Clin Immunol       Date:  2016-02-04       Impact factor: 8.317

Review 5.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

6.  Pediatric recurrent respiratory tract infections: when and how to explore the immune system? (About 53 cases).

Authors:  Mohammed El-Azami-El-Idrissi; Mounia Lakhdar-Idrissi; Sanae Chaouki; Samir Atmani; Abdelhak Bouharrou; Moustapha Hida
Journal:  Pan Afr Med J       Date:  2016-05-12

Review 7.  Specific Antibody Deficiency: Controversies in Diagnosis and Management.

Authors:  Elena Perez; Francisco A Bonilla; Jordan S Orange; Mark Ballow
Journal:  Front Immunol       Date:  2017-05-22       Impact factor: 7.561

8.  Fifth Percentile Cutoff Values for Antipneumococcal Polysaccharide and Anti-Salmonella typhi Vi IgG Describe a Normal Polysaccharide Response.

Authors:  Heidi Schaballie; Barbara Bosch; Rik Schrijvers; Marijke Proesmans; Kris De Boeck; Mieke Nelly Boon; François Vermeulen; Natalie Lorent; Doreen Dillaerts; Glynis Frans; Leen Moens; Inge Derdelinckx; Willy Peetermans; Bjørn Kantsø; Charlotte Svaerke Jørgensen; Marie-Paule Emonds; Xavier Bossuyt; Isabelle Meyts
Journal:  Front Immunol       Date:  2017-05-12       Impact factor: 7.561

9.  Pidotimod in the treatment of pediatric recurrent respiratory tract infection.

Authors:  Xia Li; Qingfang Li; Xudong Wang; Man Lu; Jingjing Shen; Qingmei Meng
Journal:  Pak J Med Sci       Date:  2019 Jul-Aug       Impact factor: 1.088

10.  Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for treatment of upper respiratory tract infections in children: a pilot study on short-term efficacy.

Authors:  Sara Manti; Giuseppe Fabio Parisi; Maria Papale; Amelia Licari; Carmelo Salpietro; Michele Miraglia Del Giudice; Gian Luigi Marseglia; Salvatore Leonardi
Journal:  Ital J Pediatr       Date:  2020-04-03       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.